



LABORATORY REPORT

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT
WX0000073111 F 02/15/1985 38 Y

Molecular

Collected: 03/17/2020 08:33 Received: 03/17/2020 08:33

Table with 6 columns: Test Name, Result, Flag, Ref-Ranges, Units, Site. Row 1: JAK2 (V617F) Mutation, Not detected, Not detected, WMRL. Row 2: Percent of WBC's with V617F Mutation, <0.1, <0.1, %, WMRL.

This procedure uses real-time polymerase chain reaction amplification and detection to quantify the percentage of white blood cells containing the V617F (G>T at position 617) point mutation in the autoinhibitory pseudokinase domain of the JAK2 protein. The lower limit of quantitation is 0.1% (1 in 1000 cells). A "Not detected" result does not preclude the presence of this or another point mutation in this gene.

This test uses commercial reagents that have not been approved or cleared by the FDA. The FDA has determined that such clearance or approval is not necessary. The performance characteristics of this procedure were determined by Warde Medical Laboratory.

This test is performed pursuant to a license agreement with Roche Molecular Systems, Inc.

Reported Date: 03/18/2020 08:27 JAK2Q

Performing Site: WMRL: WARDE MEDICAL LABORATORY 300 West Textile Road Ann Arbor MI 48108

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

6317000305 Ordered By: CLIENT CLIENT
WX0000073111 WX00000000409391
Printed D&T: 12/01/23 08:27

Kajal V. Sitwala, MD, PhD - Medical Director
Form: MM RL1
PAGE 1 OF 1